Theratechnologies Inc., founded in 1993, is a biopharmaceutical company with a strong focus on HIV, NASH, and Oncology research. Headquartered in Montreal, Quebec, Canada, the company employs over 100 people across Canada, the United States, and Europe. Theratechnologies commercializes two medicines for HIV and is actively engaged in research and development in multiple therapeutic areas.

The company's flagship products include Trogarzo® and EGRIFTA®, with ongoing research in areas like Tesamorelin for NASH and SORT1+ Technology™ for oncology. With a mission to provide hope through innovative treatments addressing unmet medical needs, Theratechnologies is committed to bringing exceptional innovations to the market. For those interested in groundbreaking therapies and cutting-edge treatments, Theratechnologies is a key player in the biopharmaceutical industry, focused on advancing healthcare for practitioners and patients globally